Ovarian Cancer Clinical Trials in Minneapolis, Minnesota

13 studies are recruiting for ovarian cancer in Minneapolis, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

   This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

   Locations

   9 in total

   Run by

   Imunon

   See if you can join NCT06915025 on ClinicalTrials.gov

2. A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

   This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

   Stage

   Phase 2

   Ages

   18 to 99

   Site

   Minnesota Oncology-Minneapolis, Minneapolis, Minnesota

   Locations

   74 in total

   Run by

   Incyte Corporation

   See if you can join NCT07023627 on ClinicalTrials.gov

3. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

   This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota

   Locations

   5 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07216105 on ClinicalTrials.gov

4. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

   The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

   Stage

   Phase 1

   Ages

   15 and older

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   22 in total

   Run by

   Xencor, Inc.

   See if you can join NCT06276491 on ClinicalTrials.gov

5. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

   This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Normunity Investigational Site, Minneapolis, Minnesota

   Locations

   18 in total

   Run by

   Normunity AccelCo, Inc.

   See if you can join NCT07182149 on ClinicalTrials.gov

6. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

   This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   518, Minneapolis, Minnesota

   Locations

   49 in total

   Run by

   Corcept Therapeutics

   See if you can join NCT06906341 on ClinicalTrials.gov

7. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

   The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα rec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Minnesota - Masonic Cancer Center, Minneapolis, Minnesota

   Locations

   9 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT04606914 on ClinicalTrials.gov

8. UNTOLD Ovarian Cancer Unmet Needs Survey

   The goal of this study is to comprehensively measure ongoing concerns and unmet needs of individuals living with ovarian cancer. To accomplish this, the UNderstanding The experience of Ovarian cancer - Life after Diagnosis (UNTOLD) study will be conducted using a mixed-methods approach. Ovarian can…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Masonic Cancer Center, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT07070726 on ClinicalTrials.gov

9. Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

   This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-g…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Minnesota Oncology Hematology PA, Minneapolis, Minnesota

   Locations

   208 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06819007 on ClinicalTrials.gov

10. Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

    The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are subs…

    Stage

    Not phased

    Ages

    50 to 74

    Site

    University of Minnesota, Minneapolis, Minnesota

    Locations

    12 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT00539162 on ClinicalTrials.gov

11. First in Human Study of TORL-1-23 in Participants With Advanced Cancer

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Minnesota, Minneapolis, Minnesota

    Locations

    14 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT05103683 on ClinicalTrials.gov

12. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage

    Not phased

    Ages

    40 and older

    Site

    Allina Health Cancer Institute, Minneapolis, Minnesota

    Locations

    17 in total

    Run by

    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov

13. A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

    The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Minnesota, Minneapolis, Minnesota

    Locations

    4 in total

    Run by

    Outpace Bio, Inc.

    See if you can join NCT07030907 on ClinicalTrials.gov